Medicina
Facultad
![Foto de Medicina](/img/uploaded/B3F8E74FDA254B3134B0031201D4E115.jpg)
![Foto de Centro de Investigación Médica Aplicada](/img/noimage_org.png)
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (180)
2024
-
Animal models of disease: Achievements and challenges
Methods in Cell Biology
-
Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1
JHEP Reports, Vol. 6, Núm. 1
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Consensus on the approach to hydrosaline overload in acute heart failure. SEMI/SEC/S.E.N. recommendations
Revista Espanola de Cardiologia, Vol. 77, Núm. 7, pp. 556-565
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Preface
Methods in Cell Biology
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver
Molecular Genetics and Metabolism Reports, Vol. 35
-
Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming
Journal of Hepatology, Vol. 79, Núm. 3, pp. 728-740
-
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Frontiers in Oncology, Vol. 13
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
Cells, Vol. 12, Núm. 15
-
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
-
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
Blood, Vol. 142, Núm. 18, pp. 1518-1528
-
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1383-1392
-
Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis
Cell death & disease, Vol. 14, Núm. 8, pp. 514